SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells $326,598.36 in Stock

Key Points

• SOPHiA GENETICS Chairman Jurgi Camblong sold 40,172 shares at an average price of $8.13, totaling $326,598.36. The Rule 10b5-1 sale was intended to cover tax withholding obligations, leaving him with 3.40 million shares.
• SOPH shares fell $0.23 to $7.15, while the company reported a quarterly EPS loss of $0.26 that missed estimates, despite revenue of $23.31 million exceeding expectations.
• Analyst sentiment is mixed, with a consensus “Hold” rating and a $10 average price target; institutional investors own approximately 31.59% of the company.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) Chairman Jurgi Camblong sold 40,172 shares of the company's stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $8.13, for a total value of $326,598.36. Following the completion of the sale, the chairman owned 3,395,650 shares in the company, valued at approximately $27,606,634.50. This represents a 1.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Thursday, September 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.66, for a total value of $65,110.00.
• On Monday, August 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.61, for a total value of $64,685.00.
• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.23, for a total value of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total value of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.29, for a total transaction of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.62, for a total transaction of $47,770.00.

SOPHiA GENETICS Price Performance

SOPH stock traded down $0.23 during trading on Wednesday, hitting $7.15. 432,750 shares of the stock traded hands, compared to its average volume of 308,157. The stock has a market cap of $599.81 million, a price-to-earnings ratio of -6.22 and a beta of 0.95. SOPHiA GENETICS SA has a one year low of $3.75 and a one year high of $8.98. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The company has a 50 day simple moving average of $7.82 and a 200 day simple moving average of $6.12.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. Equities analysts expect that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors have recently made changes to their positions in the stock. AWM Investment Company Inc. acquired a new position in SOPHiA GENETICS in the second quarter valued at about $9,809,000. Principal Financial Group Inc. raised its position in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock valued at $6,976,000 after acquiring an additional 9,800 shares during the period. Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS during the 1st quarter worth approximately $2,157,000. Sei Investments Co. acquired a new position in SOPHiA GENETICS during the first quarter valued at approximately $1,772,000. Finally, 1492 Capital Management LLC increased its stake in SOPHiA GENETICS by 8.4% in the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company's stock valued at $1,117,000 after purchasing an additional 17,406 shares in the last quarter. 31.59% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on SOPH shares. Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. HC Wainwright lifted their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, BTIG Research raised their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.